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Gabapentin (GBP) is widely used to treat epilepsy and neuropathic pain. There is
evidence that GBP can act on hyperpolarization-activated cation (HCN) channel-
mediated Ih in brain slice experiments. However, evidence showing that GBP directly
modulates HCN channels is lacking. The effect of GBP was tested using two-electrode
voltage clamp recordings from human HCN1, HCN2, and HCN4 channels expressed
in Xenopus oocytes. Whole-cell recordings were also made from mouse spinal cord
slices targeting either parvalbumin positive (PV+) or calretinin positive (CR+) inhibitory
neurons. The effect of GBP on Ih was measured in each inhibitory neuron population.
HCN4 expression was assessed in the spinal cord using immunohistochemistry. When
applied to HCN4 channels, GBP (100 µM) caused a hyperpolarizing shift in the voltage
of half activation (V1/2) thereby reducing the currents. Gabapentin had no impact on
the V1/2 of HCN1 or HCN2 channels. There was a robust increase in the time to half
activation for HCN4 channels with only a small increase noted for HCN1 channels.
Gabapentin also caused a hyperpolarizing shift in the V1/2 of Ih measured from HCN4-
expressing PV+ inhibitory neurons in the spinal dorsal horn. Gabapentin had minimal
effect on Ih recorded from CR+ neurons. Consistent with this, immunohistochemical
analysis revealed that the majority of CR+ inhibitory neurons do not express somatic
HCN4 channels. In conclusion, GBP reduces HCN4 channel-mediated currents through
a hyperpolarized shift in the V1/2. The HCN channel subtype selectivity of GBP
provides a unique tool for investigating HCN4 channel function in the central nervous
system. The HCN4 channel is a candidate molecular target for the acute analgesic and
anticonvulsant actions of GBP.
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INTRODUCTION
Gabapentin (GBP) was synthesized as a rigid lipophilic analog of gamma-aminobutyric acid
(GABA) with the intention of mimicking inhibitory neurotransmission. Although GBP was
first approved for the treatment of epilepsy it is now more commonly used as a therapy in
neuropathic pain. In addition, it is often used off-label to treat a number of medical conditions
including anxiety, alcohol and drug addiction, and bi-polar disorders (Mack, 2003). Despite
the rational design, there is no current evidence that GBP directly modulates the GABAergic
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system (Taylor et al., 2007). Instead, the widely accepted mode-of-
action of GBP is that it interacts with the α2δ protein, an accessory
subunit of voltage-gated calcium (Ca2+) channels responsible
for enhancing channel trafficking to the plasma membrane as
well as influencing their biophysical properties (Dolphin, 2016).
Gabapentin interaction with the α2δ subunit is thought to
lead to reduced voltage-gated Ca2+ channel trafficking to the
membrane surface of glutamatergic synapses, reducing excitatory
neurotransmitter release, and consequently excitability (Fink
et al., 2002). Gabapentin has also been shown to acutely block
voltage-dependent Ca2+ channels (Stefani et al., 1998; Sutton
et al., 2002) and putatively interacts with several molecular targets
including N-methyl-D-aspartic acid (NMDA) and α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors,
and KATP channels (Cheng and Chiou, 2006).
In this study, we investigate hyperpolarization-activated
cation (HCN) channels as a potential target of GBP.
Hyperpolarization-activated cation channels are encoded by
four genes, HCN1–HCN4 and are expressed in brain and cardiac
tissue (Santoro and Tibbs, 1999). Hyperpolarization-activated
cation channels carry a non-selective cationic conductance
(Ih) that regulates neuronal excitability by modulating resting
membrane potential, input resistance, and synaptic integration
(He et al., 2014). Several studies have mechanistically linked
changes in the function and expression of various HCN channels
to epilepsy and pain, making them good molecular targets in
both neurological conditions (Reid et al., 2012; Benarroch,
2013; DiFrancesco and DiFrancesco, 2015; Tibbs et al., 2016).
Furthermore, studies using hippocampal slices show that GBP
increases Ih in both pyramidal neurons (Surges et al., 2003) and
inhibitory interneurons in CA1 (Peng et al., 2011). Although
these studies imply a GBP effect on Ih currents, whether GBP
acts directly on HCN channels in isolation is not clear. Here,
we tested the effect of GBP on heterologously expressed human
HCN1, HCN2, and HCN4 channels. Our results show that GBP
shifts the voltage dependence of activation of HCN4-mediated
currents. This effect was also true for native HCN4-mediated
currents in the mouse central nervous system, with GBP shifting
the voltage dependence of activation of Ih in parvalbumin
(PV)-expressing inhibitory neurons in the spinal cord that are
known to express HCN4 channels (Hughes et al., 2013), but
not in inhibitory calretinin (CR)-expressing interneurons that
we show lack HCN4. These results highlight HCN4 channels
as a potential pharmacological target of GBP. They also suggest
that drugs with absolute HCN4 subunit selectivity may be
possible.
MATERIALS AND METHODS
Animal Ethics
Procedures using animals in this study were conducted in
accordance with the Prevention of Cruelty to Animals Act 1986,
under the guidelines of the NHMRC Code of Practice for the
Care and Use of Animals for Experimental Purposes in Australia
and were approved by the Florey Neuroscience Institute and the
Newcastle University Animal Ethics Committees. Experiments
completed in the United Kingdom were approved by the
University of Glasgow Animal Ethics Committee.
HCN cRNA In Vitro Transcription
The human(h) HCN1 transcript was cloned by Dr. Ludwig
and Dr. Stieber. The pcDNA3 hHCN1, and pSGEM hHCN4
clones came from on-going collaborations with Dr. Lerche. The
pcDNA3 hHCN2 clone was obtained from Dr. Biel (Ludwig
et al., 1999). The HCN1 and HCN2 inserts were sub-cloned into
the oocyte expression vector, pGEMHE-MCS and confirmed by
DNA sequencing (Department of Pathology, The University of
Melbourne, Australia). In vitro synthesis of cRNA was performed
using the mMessage mMachine R© T7 transcription kit (Ambion,
Foster City, CA, United States).
HCN Two-Electrode Voltage Clamp
Experiments in Oocytes
Oocytes from Xenopus laevis were prepared as previously
described (Dibbens et al., 2010). Briefly, 50 nl of cRNA-encoding
human HCN subunits (12.5 ng/µl; concentration confirmed
spectrophotometrically and by gel analysis) was injected into
stage V–VI oocytes (Dumont’s classification; 1200–1300 µm
in diameter) using the Roboocyte (Multi Channel Systems,
Reutlingen, Germany) and the oocytes were incubated for
2 days at 15◦C prior to experimentation. For heteromeric
HCN combinations, equal concentrations of each subunit were
premixed and injected into the oocytes.
Oocytes were perfused with a bath solution comprising of
(in millimolar) 96 KCl, 2 NaCl, 2 MgCl2, and 10 HEPES (pH
7.5 using KOH). Following baseline readings, oocytes were
perfused with bath solution only (vehicle control) or bath
solution containing GBP (50 or 100 µM) for 1 min before
recording. Voltage clamp experiments were performed using
Roboocyte and Roboocyte2 systems at room temperature (22–
25◦C). Oocytes were impaled with two glass electrodes containing
1.5 M potassium acetate and 0.5 M KCl, clamped at a holding
potential of −30 mV. Incremental 5 mV voltage steps (−95 to
−30 mV for hHCN1, −100 to −45 mV for hHCN2, −110 to
−45 mV for hHCN4, and −110 to −30 mV for heteromeric
hHCN2+4) were applied for 15 s, followed by a step to−100 mV
for 2 s. Comparisons of Ih under each condition were made
using normalized G–V relationships, where peak tail current
amplitudes recorded during the−100 mV test pulse were divided
by the largest peak tail current, plotted against prepulse voltage
and fit with a Boltzmann function (GraphPad Prism 7; GraphPad
Software, La Jolla, CA, United States). The time to half the peak
steady-state amplitude was used as a measure of the rate of HCN
channel activation at various voltages.
Mouse Spinal Cord Slice
Electrophysiology
Spinal cord slices were prepared as previously described (Graham
et al., 2003). Transgenic mice (age 4–8 months) expressing
enhanced green fluorescent protein (eGFP) in CR (n = 6
mice) (Caputi et al., 2009) and PV (n = 7 mice) (Meyer
et al., 2002) positive neurons, referred to hereafter as CReGFP
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and PVeGFP, respectively, were anesthetized with ketamine
(intraperitoneally at 100 mg kg−1) and decapitated. The spinal
cord was rapidly dissected free of the vertebral column and
placed in ice-cold sucrose substituted artificial cerebrospinal fluid
(aCSF) containing (in millimolar): 250 sucrose, 25 NaHCO2,
10 glucose, 2.5 KCl, 1 NaH2PO4, 1 MgCl2, and 2.5 CaCl2 for
cutting. Parasagittal spinal cord slices (L1–L5; 200 µm thick)
were prepared using a vibratome (Camden 7000 smz; Campden
Instruments, Loughborough, Leicestershire, United Kingdom)
and transferred to an incubation chamber containing aCSF
(118 mM NaCl substituted for sucrose) saturated with carbogen
gas (consisting of 95% O2 and 5% CO2). Slices were allowed
to equilibrate for at least 1 h at room temperature prior
to recording. Slices were transferred to a recording chamber
and constantly superfused with carbogen-bubbled aCSF at a
flow rate of ∼2 ml/min. Tetrodotoxin (TTX) (1 µM) was
included in the aCSF to prevent unclamped sodium spikes
contaminating traces. All recordings were made at room
temperature from visualized inhibitory CReGFP+ or PVeGFP+
neurons in the spinal dorsal horn under fluorescence using a
488 nm excitation and 508 nm emission filter set. Importantly,
CReGFP+ neurons include inhibitory and excitatory populations
in the spinal dorsal horn; however, the inhibitory subtype
is easily distinguished in spinal slices by extensive dendritic
arbors in the rostrocaudal plane (Smith et al., 2015). In
contrast, PVeGFP+ dorsal horn neurons are predominantly
inhibitory (Hughes et al., 2012). Patch pipettes (6–8 M)
were filled with internal solution containing (in millimolar):
135 K-gluconate, 6 NaCl, 2 MgCl2, 10 HEPES, 0.1 EGTA,
2 MgATP, 0.3 NaGTP, and 0.2% Neurobiotin (pH 7.3 with
KOH).
Ih currents were studied under voltage-clamp from a holding
potential of−50 mV. The I–V relationship for Ih was determined
by delivering incrementing prepulses in 5 mV from −100
to −50 mV (2 s duration) followed by a 1 s test pulse at
−100 mV (10 s sweep intervals). These data were collected at
both baseline and following bath application of GBP (100 µM)
for 3–5 min. All data were acquired using a Multiclamp 700B
amplifier (Molecular Devices, Sunnyvale, CA, United States),
digitized online (sampled at a 10–20 kHz and filtered at
5 kHz), and stored using Axograph X software (Axograph
Scientific, Sydney, Australia). Recordings were only included
for analysis if the series resistance was <30 M, filtered at
5 kHz and did not change more than 10% throughout the
recording. Data were analyzed offline using Axograph software.
Normalized G–V relationships were constructed using the tail
currents recorded during each −100 mV test pulse response,
divided by the largest peak tail current, plotted against prepulse
voltage and fit with a Boltzmann curve to determine V1/2 and
slope.
Immunohistochemistry
A total of three adult male C57Bl6 mice (20–22 g) were deeply
anesthetized with pentabarbitone and perfused transcardially
with 4% depolymerized formaldehyde. The lumbar spinal cord
was removed and post-fixed in the same solution for an
additional 2 h. Spinal cord sections (60 µm thick, transverse
planes) were cut on a vibratome and subsequently incubated in
50% ethanol for 30 min to enhance antibody penetration.
Free-floating sections were incubated in goat anti-
CR (1:1000; SWANT, Bellinoza, Switzerland; Schiffmann
et al., 1999), rabbit anti-Pax2 (1:1000; Invitrogen, Paisley,
United Kingdom; Dressler and Douglass, 1992), and mouse
anti-HCN4 (1:500; UC Davis/NIH NeuroMab Facility, Davis,
CA, United States; Giesbrecht et al., 2010; Khurana et al.,
2012). Hyperpolarization-activated cation-4 labeling was
visualized using a tetramethylrhodamine kit (PerkinElmer
Life Sciences, Boston, MA, United States) for tyramide signal
amplification as described previously (Hughes et al., 2012),
whereas immunolabeling for CR and Pax2 was visualized
using species-specific secondary antibodies conjugated to Alexa
647 and Pacific Blue, respectively. All primary and secondary
antibody cocktails were made up in 0.3 M phosphate-buffered
saline with 0.3% Triton X-100. Sections were incubated in
primary antibodies for 72 h and in secondary antibodies for
12–18 h at 4◦C.
Representative sections from each animal were scanned
on a confocal microscope (Zeiss LSM710, Hemel Hempstead,
United Kingdom). Mosaics of overlapping confocal image stacks
centered on lamina II were collected using a 40× objective (0.9
digital zoom, 1 µm z-separation) to determine the expression
of HCN4 immunolabeling in Pax2-expressing CR cells. These
mosaics were analyzed off-line using “Neurolucida for Confocal”
software (MicroBrightField, Colchester, VT, United States) to
determine the expression pattern of HCN4 immunolabeling in
the cell bodies of Pax2-expressing CR cells. Calretinin cells that
expressed Pax2 were initially identified, before revealing the
HCN4 channel to determine the presence of immunolabeling,
as described previously (Hughes et al., 2013). Cells were
defined as expressing HCN4 if immunolabeling was confined
to the cell membrane of individual cells, determined by
following individual cells throughout the z-series of the confocal
stack.
Drugs and Statistics
Tetrodotoxin was purchased from Alomone Laboratories
(Jerusalem, Israel), and GBP was purchased from Tocris
Bioscience (Bristol, United Kingdom). Drugs were stored at
1000× final concentration and diluted in oocyte bath solution
or aCSF prior to application. All data were pooled and represent
means ± standard error of the mean (SEM). Data sets were
compared using Student’s t-test unless stated (GraphPad Prism
7; GraphPad Software, La Jolla, CA, United States). An F test
was applied to determine equality of variance before parametric
statistical analysis was applied (GraphPad Prism). Differences
were deemed statistically significant when p< 0.05.
RESULTS
GBP Changes the Biophysical Properties
of HCN4 Channels
Gabapentin (100 µM) had a visual impact on several HCN4
channel biophysical properties (Figures 1A,B; n = 50). As
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FIGURE 1 | HCN4 channel function is reduced by GBP. (A) Raw HCN4 channel-mediated steady-state (left) and tail currents (right) before and after GBP. (B)
Average steady-state current before and after GBP. (C) Average 100 µM GBP to vehicle steady-state current ratio at various voltages. (D) Average 100 µM GBP to
vehicle time to half-activation ratio at various voltages. (E) Normalized conductance–voltage relationship constructed from tail currents. (F) Average shift (1) in the
voltage of half-activation and slope of HCN4 channel by 100 µM GBP and vehicle control, relative to baseline measurements. ∗∗p < 0.0001.
contemporaneous vehicle controls revealed changes in several of
the HCN4 biophysical properties statistical analysis was made
by comparing the relative change caused by GBP (100 µM)
to the relative change observed in vehicle control. Gabapentin
caused a significant reduction in steady-state current across
all voltages relative to vehicle control (n = 23) (Figure 1C;
p < 0.0001). There was also a significant slowing in the time to
activation across a range of voltages (Figure 1D; p< 0.0001). The
normalized conductance–voltage relationship of HCN4 currents
was left-shifted by ∼5 mV after GBP (100 µM) application
(Figures 1E,F). Half activation voltage (V1/2), estimated by a
Boltzmann fit was significantly different relative to vehicle control
(Figure 1F; p< 0.0001). A significant difference in the slope of the
curve between baseline and GBP was also observed (Figure 1F;
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FIGURE 2 | HCN1 channels are minimally affected by GBP. (A) Raw HCN1 channel-mediated steady-state (left) and tail currents (right) before and after 100 µM
GBP. (B) Average steady-state current before and after GBP. (C) Average 100 µM GBP to vehicle steady-state current ratio at various voltages. (D) Average 100 µM
GBP to vehicle time to half-activation ratio at various voltages. (E) Normalized conductance–voltage relationship constructed from tail currents. (F) Average shift (1)
in the voltage of half-activation and slope of HCN1 channel by 100 µM GBP and vehicle control, relative to baseline measurements.∗p < 0.05.
p < 0.0001). GBP (50 µM) had no effect on V1/2 (control
V1/2 = 81.2 ± 2.0 mV vs. GBP 50 µM V1/2 = 81.4 ± 1.4 mV,
n= 7, p= 0.9) or slope (control slope= 6.3± 0.2 vs. GBP 50 µM
slope= 7.3± 0.5 mV, n= 7, p= 0.1).
GBP Effect on HCN1 and HCN2 Channels
Gabapentin (100 µM) had no impact on the steady-state
currents of HCN1 channel-mediated current relative to baseline
(Figures 2A,B; n = 30). Consistent with this, GBP (100 µM)
had no effect on steady-state current across all voltages relative to
vehicle control (n = 14) (Figure 2C). Gabapentin (100 µM) did
slightly slow HCN1 activation kinetics across a range of voltages
(Figure 2D; p < 0.05). The normalized conductance–voltage
relationship of HCN1 currents was unchanged (Figure 2E),
with no significant difference in V1/2 relative to vehicle control
(Figure 2F; p = 0.2). Similarly, the slope of the HCN1
conductance–voltage relationship was unaffected (Figure 2F;
p= 0.5).
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FIGURE 3 | HCN2 channels are unaffected by GBP. (A) Raw HCN2 channel-mediated steady-state (left) and tail currents (right) before and after 100 µM GBP. (B)
Average steady-state current before and after GBP. (C) Average 100 µM GBP to vehicle steady-state current ratio at various voltages. (D) Average 100 µM GBP to
vehicle time to half-activation ratio at various voltages. (E) Normalized conductance–voltage relationship constructed from tail currents. (F) Average shift (1) in the
voltage of half-activation and slope of HCN2 and HCN2+4 channels by 100 µM GBP and vehicle control, relative to baseline measurements.
Gabapentin had no impact on the steady-state HCN2 channel
currents relative to baseline (Figures 3A,B; n = 22). Gabapentin
(100 µM) also had no effect on steady-state current across
all voltages relative to vehicle control (n = 12) (Figure 3C).
The activation kinetics of HCN2 channels in the presence of
GBP was not affected (Figure 3D). Normalized conductance–
voltage relationship was not different from baseline (Figure 3E),
with no significant change in V1/2 (Figure 3F; p = 0.9) or
slope (Figure 3F; p = 0.4) relative to vehicle control. Given
the potential for the formation of heteromeric HCN channels
(Biel et al., 2009; Wahl-Schott and Biel, 2009), we tested
the impact of GBP on oocytes co-injected with HCN4 and
HCN2 channels. Gabapentin significantly left-shifted V1/2 of
heteromeric HCN2+4 currents (n = 25) compared to vehicle
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FIGURE 4 | HCN4 expression in mouse dorsal horn populations. (A) Immunolabeling for calretinin (CR) (green) and HCN4 (red) overlaps substantially in the superficial
laminae of the spinal dorsal horn, but rarely in the same cells (asterisk and inset shows the lack of HCN4 labeling in a CR neuron). (B and C) HCN4 immunolabeling is
absent in Pax2-expressing (blue) CR+ neurons (arrowheads), however, HCN4 is detected in many neurons lacking Pax2 (arrows). Scale bar = 10 µm.
control (n = 7) (Figure 3F; p < 0.05). The impact of GBP
on currents mediated by HCN2+4 heteromeric channels was
significantly less than that observed for HCN4 homomeric
channels (HCN2+4 GBP 100 µM 1V1/2 = −3.4 ± 0.4 mV
vs. HCN4 GBP 100 µM 1V1/2 = −5.0 ± 0.3 mV, p < 0.05).
Interestingly, there was no effect of GBP (100 µM) on the
Boltzmann slope (Figure 3F; p= 0.8).
GBP Reduces HCN4 Channel Function in
PV+ Inhibitory Neurons in Mouse Spinal
Cord
Targeted-whole-cell patch-clamp experiments have shown that
PV+ neurons in laminae II and III of the spinal cord have
a high incidence of Ih sub-threshold currents, and that ∼80%
of these neurons express HCN4 channels (Hughes et al., 2012,
2013). Here, we assessed whether another population of lamina
II inhibitory interneurons also known to have a high incidence
of Ih currents express HCN4 channels. Approximately 15%
of CR+ interneurons in lamina II express Pax2, an inhibitory
interneuron marker, and these cells have a high incidence
of Ih (Smith et al., 2015, 2016). Our immunocytochemical
studies found that HCN4 immunolabeling was absent in the cell
bodies of inhibitory (Pax2-expressing) CR+ neurons in lamina
II (0 of 205 cells; 60, 66, and 79 cells analyzed per animal).
Hyperpolarization-activated cation-4 immunolabeling in lamina
II was seen in many cells that expressed Pax2 but lacked CR,
and occasionally in CR+ cells that lacked Pax2, although this was
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FIGURE 5 | GBP reduces Ih recorded from PV+ inhibitory neurons. (A) Raw steady-state Ih (left) and tail currents (right) before and after application of 100 µM GBP
recorded from PV+ neurons. (B) Average steady-state current before and after GBP recorded from PV+ neurons. (C) Average 100 µM GBP to vehicle steady-state
current ratio at various voltages. (D) Average 100 µM GBP to vehicle time to half-activation ratio at various voltages. (E) Normalized conductance–voltage
relationship constructed from tail currents recorded from PV+ neurons. (F) Average shift (1) in the voltage of half-activation and slope of PV+ neurons by 100 µM
GBP and vehicle control, relative to baseline measurements. ∗p < 0.05.
not analyzed formally (Figure 4). As PV+ and CR+ inhibitory
populations therefore appear to have distinct somatic HCN4
expression patterns, they represent good targets to assess HCN4-
dependent GBP effect on Ih currents. This was assessed further in
targeted patch clamp recordings made in spinal cord slices from
PVeGFP or CReGFP neurons (Hughes et al., 2012; Smith et al.,
2016).
Whole-cell patch-clamp recordings from PVeGFP neurons
were used to measure Ih (Figures 5A,B, n = 10). The
addition of the broad-spectrum blocker, ZD7288 (100 µM)
abolished currents evoked by hyperpolarizing voltage excursions
(n = 3, Supplementary Figures S1A,B). Gabapentin (100 µM)
significantly reduced steady-state current across all voltages
except −65 mV relative to vehicle control (Figure 5C;
Frontiers in Pharmacology | www.frontiersin.org 8 August 2017 | Volume 8 | Article 554
fphar-08-00554 August 17, 2017 Time: 18:29 # 9
Tae et al. Gabapentin and HCN4 Kinetics
FIGURE 6 | GBP minimally affects Ih recorded from CR+ inhibitory neurons. (A) Raw steady-state Ih (left) and tail currents (right) before and after application of
100 µM GBP recorded from CR+ neurons. (B) Average steady-state current before and after GBP recorded from CR+ neurons. (C) Average 100 µM GBP to vehicle
steady-state current ratio at various voltages. (D) Average 100 µM GBP to vehicle time to half-activation ratio at various voltages. (E) Normalized
conductance–voltage relationship constructed from tail currents of CR+ neurons. (F) Average shift (1) in the voltage of half-activation and slope of CR+ neurons by
100 µM GBP and vehicle control, relative to baseline measurements. ∗p < 0.05.
n = 10, p < 0.05). There was also a significant slowing
in the time to activation at −90 and −95 mV (Figure 5D;
p < 0.05). Similar to heterologous expressed HCN4 channels,
the normalized conductance–voltage relationship was left-
shifted by ∼5 mV relative to baseline (Figures 5E,F). V1/2
estimated by a Boltzmann fit was significantly shifted relative
to vehicle control (Figure 5F; p < 0.05). No significant
difference in the slope of the curve was observed (Figure 5F;
p= 0.9).
In recordings from CReGFP neurons, GBP had no impact on
biophysical properties (Figures 6A,B; n = 12) including steady-
state current relative to vehicle control (Figure 6C, n= 12). There
was a small but significant slowing in the time to activation across
at −90 to −100 mV (Figure 6D; p < 0.05). The normalized
conductance–voltage relationship was unchanged (Figure 6E)
with V1/2 and curve slope estimated by a Boltzmann fit not
significantly different relative to vehicle control (Figure 6F;
p = 0.7 and 0.4, respectively). Furthermore, GBP (100 µM)
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shifted V1/2 significantly more in PV+ neurons compared to
CR+ neurons (CR+ GBP 100 µM 1V1/2 = −0.7 ± 1.0 mV vs.
PV+ GBP 100 µM1V1/2 =−5.2± 1.5 mV, p< 0.05). Therefore,
our recordings showed that V1/2 of Ih was shifted significantly by
GBP in a population that exhibits robust expression of HCN4,
whereas Ih is insensitive to GBP in a population that lacks HCN4.
DISCUSSION AND CONCLUSION
Hyperpolarization-activated cation channels are potential drug
targets for several disease states including pain and epilepsy (Reid
et al., 2012; Benarroch, 2013; DiFrancesco and DiFrancesco,
2015; Tibbs et al., 2016). The different biophysical properties
and cellular distributions of the varying HCN subtypes
give them unique roles within the central nervous system.
Hyperpolarization-activated cation channel isoform-selective
modulation is therefore likely to generate different efficacy
and side-effect profiles. A major issue in the field has been
the discovery of HCN isoform-selective compounds (Novella
Romanelli et al., 2016). Here, we demonstrate that GBP has
a robust impact on HCN4-mediated currents. The left-shift in
activation voltage was observed in both heterologously expressed
human channels and Ih of PV+ inhibitory dorsal horn neurons
known to express HCN4 channels (Hughes et al., 2012, 2013).
Gabapentin was essentially without effect on heterologously
expressed human HCN1 and HCN2 channels and in CR+
inhibitory dorsal horn neurons, which exhibit Ih currents but
do not express somatic HCN4 channels. To the best of our
knowledge, our data provide the first evidence of a drug with
almost full selectivity for the HCN4 channel subtype over other
centrally expressed HCN channels. Moreover, GBP provides a
unique tool to investigate the functional role of HCN4 channels
in the central nervous system.
The native neuronal environment is complex, with several
unknown variables that include exact HCN channel subunit
composition and unknown constitutive second messenger
modulation. Unlike heterologous expressed homomeric HCN4
channels, recordings from PV+ inhibitory dorsal horn neurons
failed to show a GBP-mediated change in the Boltzmann slope.
Interestingly, in expressed heteromeric HCN2+4 channels GBP
did not affect the slope despite having a significant effect of on
V1/2. This is consistent with the idea that Ih in PV+ neurons is
mediated by heteromeric HCN channels (Hughes et al., 2012). It
is also important to note that we have not ruled out a contribution
of the HCN3 channel, although there is no evidence to suggest
that this subunit is expressed in PV+ inhibitory dorsal horn
neurons. Gabapentin subtly increased the time to half activation
in CR+ neurons that lack HCN4 channels. This is consistent with
the small increase caused by GBP in homomeric HCN1 channels,
although further efforts are required to confirm the exact HCN
channel expression patterns in these cells. In summary our
in vitro and ex vivo results are consistent with the idea that GBP
can modulate Ih in a subunit specific manner.
One important finding from this study was the apparent lack
of somatic expression of HCN4 channels in the Pax2-expressing
CR cells in lamina II. Although HCN channels containing HCN1
and HCN2 subunits are known to be preferentially expressed
in the distal dendrites of cortical and hippocampal pyramidal
cells (Notomi and Shigemoto, 2004), this restricted expression
pattern is not seen for the HCN4 subunit in the same cells nor
has it been described in neurons from other subcortical regions
(Hughes et al., 2013). On the contrary, several examples of cells
that express HCN subunits in both the brainstem and spinal cord
show continuity in HCN subunit expression throughout their
somatodendritic domain (Milligan et al., 2006; Hughes et al.,
2013). Although we cannot dismiss the possibility of a restricted
pattern of HCN4 expression confined to dendritic domains in
Pax2-expressing CR using the approaches described here, we
conclude that our failure to see HCN4 labeling in the cell body
of these cells reflects the labeling patterns described previously
for HCN subunits in the spinal cord, and is therefore consistent
with an absence of HCN4 elsewhere in the cell.
Gabapentin had no impact on expressed HCN4 channel
biophysical properties at 50 µM. Hundred micromolar is likely
to be at the upper end of the expected plasma concentrations of
patients taking high doses of the drug (Berry et al., 2003) with
cerebral spinal fluid levels likely to be less (Ben-Menachem et al.,
1995). This said it is not possible to estimate the concentration
of GBP achieved at receptors in the central nervous system. It
is therefore not unreasonable to consider HCN4 channels as a
potential molecular target of GBP. Pharmacological studies have
demonstrated that blocking HCN channels can have analgesic
and anticonvulsant effects, for example, systemic injection of
the broad-spectrum HCN blocker, ZD7288, reduces neuropathic
pain behavior in rodent models (Chaplan et al., 2003; Lee et al.,
2005; Luo et al., 2007). Interestingly, direct cortical infusion of
ZD7288 can similarly produce analgesic effects (Cordeiro Matos
et al., 2015; Koga et al., 2015). Moreover, ivabradine, a clinically
used broad-spectrum blocker of HCN channels can suppress
mechanical allodynia in rodent models of neuropathic pain (Noh
et al., 2014; Young et al., 2014). To date there is no evidence
that specifically implicates HCN4 channels in the pathogenesis
of neuropathic pain. However, HCN4 channels are well placed to
modulate the activity of PV+ neurons that have been shown to be
critical modulators of mechanical hypersensitivity that develops
following nerve injury (Petitjean et al., 2015).
Broad-spectrum block with ZD7288 also reduces seizure
susceptibility in several animal models of epilepsy including
electrically induced paroxysmal discharges (Kitayama et al.,
2003), generalized seizures in Mongolian gerbils (Matsuda et al.,
2008), and maximal electroshock-induced seizures (Luszczki
et al., 2013). There is some associative evidence suggesting
increased HCN4 channel function may be part of the mechanism
underlying hyperexcitability in epilepsy. For example, HCN4
mRNA levels are increased in the pilocarpine rodent model of
temporal lobe epilepsy, which correlates with an increase in Ih in
dentate granule cells (Surges et al., 2012). Also, thalamocortical
neurons switch from predominant HCN2 to a predominant
HCN4 channel expression pattern in a cortical stroke model
in which seizures developed (Paz et al., 2013). Clearly, future
investigations are needed to identify the role HCN4 channels play
in both seizure susceptibility and neuropathic pain, and whether
the acute effects of GBP can be attributed to this molecular target.
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Hyperpolarization-activated cation-4 channels are highly
expressed in cardiac tissue, especially in the sinoatrial node,
where they are a major driver of rhythmicity (Scicchitano et al.,
2012). Given this expression pattern, along with our data, it is
noteworthy that cardiovascular adverse events are rarely reported
in patients taking GBP. This is consistent with the fact that even
significant block of HCN4 channel function with the clinically
used broad-spectrum Ih blocker, ivabradine, generally results
only in a self-limiting bradycardia (Savelieva and Camm, 2008).
Careful evaluation may be warranted in patients taking GBP
to gauge whether the shift in HCN4 V1/2 observed here is
sufficient to subtly alter cardiac function. Interestingly, a recent
meta-analysis of GBP use on hemodynamic response during
endotracheal intubation concluded that the drug significantly
attenuated increases in heart rate and blood pressure due
to the procedure (Doleman et al., 2016). This is consistent
with HCN4 channel block, although it could equally reflect
other physiological changes including the attenuation of the
sympathetic stress response elicited by intubation (Todd et al.,
2012).
Our results are not consistent with experiments completed in
hippocampal slices. In contrast to the GBP-mediated reduction in
Ih that we see, Ih currents are increased in both CA1 pyramidal
and inhibitory interneurons (Peng et al., 2011; Surges et al., 2003).
This is surprising as HCN1 and HCN2 are highly expressed in
the CA1 region of the rat hippocampus (Notomi and Shigemoto,
2004) yet, GBP had minimal impact on human HCN1 or HCN2
channels expressed in oocytes suggesting that this effect may be
through a secondary mechanism. This discrepancy may also be
due to the absence of neuron-specific trafficking and intracellular
signaling mechanisms in the oocyte expression system, although
the lack of a GBP effect in Ih in CR+ dorsal horn neurons,
which lack somatic HCN4 channels, partly compensates for this
limitation. Regardless, it will be important for future work to
investigate how GBP modulates Ih in regions of the brain in
which HCN4 is more robustly expressed.
CONCLUSION
We provide evidence that GBP can reduce human HCN4 channel
function by causing a hyperpolarizing shift in the voltage of
activation. This action is mostly limited to HCN4 channels, with
minimal changes observed for HCN1 channels and none for
HCN2 channels. Similarly, the Ih in spinal cord PV+ inhibitory
neurons is reduced by GBP. There is a clear paucity of HCN
subunit selective drugs currently available (Novella Romanelli
et al., 2016). Gabapentin provides a good lead compound
on which other selective compounds could be developed.
Further, efforts aimed at understanding the structural–function
relationship of GBP binding to HCN4 channels will help in
this endeavor. Gabapentin action on HCN4 channels has the
potential to contribute to analgesic and anticonvulsant activity,
however, future experiments will be needed to establish a causal
link between HCN4 channel block and reduced neuronal/circuit
excitability within the central nervous system.
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